|
Video: What is a Stock Split?
|
|
Benitec Biopharma is a clinical-stage biotechnology company focused on the development of genetic medicines. The platform, called DNA-directed RNA interference, combines RNA interference with gene therapy to create medicines that facilitate sustained silencing of disease-causing genes following a single administration. Co. is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a genetic disorder. BB-301 is an adeno-associated viral vectors -based gene therapy designed to silence the expression of the disease-causing gene (to slow, or halt, the biological mechanisms underlying disease progression in OPMD). According to our BNTC split history records, Benitec Biopharma has had 3 splits. | |
|
Benitec Biopharma (BNTC) has 3 splits in our BNTC split history database. The first split for BNTC took place on November 18, 2019. This was a 1 for 10 reverse split, meaning for each 10 shares of BNTC owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 100 share position following the split. BNTC's second split took place on April 15, 2020. This was a 2 for 3 reverse split, meaning for each 3 shares of BNTC owned pre-split, the shareholder now owned 2 shares. For example, a 100 share position pre-split, became a 66.6666666666667 share position following the split. BNTC's third split took place on July 26, 2023. This was a 1 for 17 reverse split, meaning for each 17 shares of BNTC owned pre-split, the shareholder now owned 1 share. For example, a 66.6666666666667 share position pre-split, became a 3.92156862745098 share position following the split.
When a company such as Benitec Biopharma conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the BNTC split history from start to finish, an original position size of 1000 shares would have turned into 3.92156862745098 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Benitec Biopharma shares, starting with a $10,000 purchase of BNTC, presented on a split-history-adjusted basis factoring in the complete BNTC split history.
Growth of $10,000.00
With Dividends Reinvested
|
Start date: |
06/25/2014 |
|
End date: |
04/23/2024 |
|
Start price/share: |
$1,479.00 |
|
End price/share: |
$6.86 |
|
Starting shares: |
6.76 |
|
Ending shares: |
6.77 |
|
Dividends reinvested/share: |
$0.77 |
|
Total return: |
-99.54% |
|
Average Annual Total Return: |
-42.09% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$46.40 |
|
Years: |
9.84 |
|
|
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
06/25/2014 |
|
End date: |
04/23/2024 |
|
Start price/share: |
$1,479.00 |
|
End price/share: |
$6.86 |
|
Dividends collected/share: |
$0.77 |
|
Total return: |
-99.48% |
|
Average Annual Total Return: |
-41.47% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$51.53 |
|
Years: |
9.84 |
|
|
|
Date |
Ratio |
11/18/2019 | 1 for 10 | 04/15/2020 | 2 for 3 | 07/26/2023 | 1 for 17 |
|
|